Integra Sells $450 Million Of 9.500% Secured Notes And Rebuilds Its $1.65 Billion Credit Facility
The old $1.3 billion revolver and $775 million term loan were repaid in full, with no early termination penalties, the 8-K says.
Integra LifeSciences closed a private offering of $450 million of 9.500% senior secured notes due 2033 and amended its bank credit facility to a size of up to $1.65 billion, according to an 8-K filed Monday. It used the proceeds to repay its previous credit agreement in full.
What the 8-K says
The new credit agreement, with Bank of America as administrative agent, has three pieces: a $600 million revolver and a $600 million term loan A, both with five-year maturities, and a $450 million term loan B with a seven-year maturity. The company's obligations are guaranteed by substantially all of its wholly owned domestic subsidiaries and secured by substantially all of its assets.
Term loan B borrowings carry an applicable rate of 4.25% over Term SOFR, a benchmark floating rate. The revolver and term loan A start at 3.00%. After the compliance certificate for the quarter ending December 31, 2026, that rate will range from 2.00% to 3.25%, depending on Integra's leverage ratio. The revolver also carries a commitment fee, fixed at 0.30% until then and ranging from 0.20% to 0.35% afterward.
The notes pay 9.500% a year, semiannually on May 1 and November 1, starting May 1, 2027, and mature November 1, 2033. They rank equally with the credit agreement debt and share first-priority liens on the collateral.
What it replaces
The old agreement was a $1.3 billion revolver and a $775 million term loan, both due March 24, 2028, subject to certain springing maturity conditions. Integra repaid all loans, with accrued interest and fees, and ended the revolving commitments. The company said it incurred no early termination penalties.
The press release says the net proceeds and credit facility borrowings also covered fees and expenses. The notes were sold only to qualified institutional buyers and certain non-U.S. persons, and are not registered under the Securities Act.
Redemption terms and covenants
Before November 1, 2029, Integra may redeem some or all of the notes at par plus a make-whole premium. It may also redeem up to 40% of the principal using proceeds of certain equity offerings, at 109.500%, provided at least 50% of the original amount stays outstanding.
A change of control would require an offer to buy the notes at 101% of principal. The indenture, with Truist Bank as trustee, limits additional debt, liens, dividends, buybacks, investments, asset sales, affiliate dealings and mergers.
The first coupon on the notes is due May 1, 2027, and the December 31, 2026 quarter's compliance certificate will set pricing on the revolver and term loan A within the 2.00% to 3.25% range.
Sources
- 8-K Filing — INTEGRA LIFESCIENCES HOLDINGS CORP (IART) — SEC EDGAR
- Exhibit d142199dex991.htm — INTEGRA LIFESCIENCES HOLDINGS CORP 8-K exhibit — SEC EDGAR
More on Integra LifeSciences
- Integra's Tissue Reconstruction Unit Clears Goodwill Test With 11.3% To Spare, A Year After $511.4 Million Write-Off
- Integra CEO Expects To 'Lose Some Business' In Neurosurgery As Mayfield Clamp Supply Runs Short Into 2027
- Integra Posts $14.9 Million Profit Against Year-Ago Loss, With Revenue Up 2.3% To $411.2 Million